Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Reaffirmed by Oppenheimer

Oppenheimer restated their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR - Free Report) in a report published on Wednesday morning, Benzinga reports. The firm currently has a $18.00 price objective on the stock.

VYGR has been the subject of a number of other reports. Guggenheim assumed coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a buy rating and a $22.00 price target for the company. HC Wainwright assumed coverage on Voyager Therapeutics in a research note on Tuesday, March 19th. They set a buy rating and a $30.00 price target for the company. Citigroup started coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They issued a buy rating and a $16.00 price objective on the stock. Wedbush reduced their price objective on shares of Voyager Therapeutics from $10.00 to $8.00 and set a neutral rating for the company in a research report on Tuesday. Finally, StockNews.com downgraded shares of Voyager Therapeutics from a buy rating to a hold rating in a report on Monday. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Voyager Therapeutics currently has an average rating of Moderate Buy and a consensus price target of $18.00.

Voyager Therapeutics Stock Up 1.1 %

NASDAQ VYGR traded up $0.09 on Wednesday, hitting $8.57. The stock had a trading volume of 510,531 shares, compared to its average volume of 840,423. The company's 50-day moving average is $8.80 and its two-hundred day moving average is $8.09. The stock has a market cap of $466.12 million, a price-to-earnings ratio of -169.97 and a beta of 0.98. Voyager Therapeutics has a one year low of $6.06 and a one year high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a negative return on equity of 1.49% and a negative net margin of 2.56%. The firm had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. On average, sell-side analysts anticipate that Voyager Therapeutics will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock worth $30,087,000 after purchasing an additional 702,030 shares during the period. Armistice Capital LLC grew its holdings in shares of Voyager Therapeutics by 15.3% during the third quarter. Armistice Capital LLC now owns 4,178,000 shares of the company's stock valued at $32,380,000 after buying an additional 554,000 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Voyager Therapeutics during the fourth quarter valued at $1,569,000. Kestra Advisory Services LLC acquired a new position in Voyager Therapeutics during the third quarter valued at $980,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in Voyager Therapeutics during the 3rd quarter worth about $887,000. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.